TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06007820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large Volume Thoracocentesis
Description: Large Volume Thoracocentesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pigtail Catheter
Description: Pigtail Catheter
Study: NCT06502782

Intervention type: DIAGNOSTIC_TEST
Intervention: digital assesment
Description: Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.

Intervention type: DIAGNOSTIC_TEST
Intervention: digital assesment
Description: Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
Study: NCT05109624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prolonged prone position ventilation
Description: patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
Study: NCT04867733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micropatch (microneedle patch)
Description: Each micropatch contains an array of 50 microneedles.
Study: NCT05088057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
Study: NCT04828746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Skin Marking
Description: Using ultrasound for skin marking pre-procedure
Study: NCT06023485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball use during subcutaneous injection
Description: The effect of stress ball use on pain during subcutaneous injection
Study: NCT06514638

Intervention type: OTHER
Intervention: Ultrasound imaging
Description: Images of the vastus medialis were taken with the subject being lateral decubitus.
Study: NCT05088057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
Study: NCT06097663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: Active MAS825 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAS825 Placebo
Description: MAS825 placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: Oral tablet of DFV890 active once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: Oral tablet of DFV890 active once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: Oral tablet of DFV890 active once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFV890 placebo
Description: Oral tablet of DFV890 placebo once daily
Study: NCT06141447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin + normal saline
Description: 40 units IV oxytocin once in a 1000 mL bag of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1000 mL bag of normal saline alone
Study: NCT05711134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback on Individual Practice Patterns
Description: Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback on Individual Practice Patterns
Description: Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
Study: NCT05900544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: System implementation of patient-centered incidental findings report
Description: For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
Study: NCT03825302

Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine challenge
Description: Methacholine inhalation challenge will be administered to both male and females with asthma

Intervention type: DIAGNOSTIC_TEST
Intervention: Methacholine challenge
Description: Methacholine inhalation challenge will be administered to both male and females with asthma

Intervention type: DIAGNOSTIC_TEST
Intervention: Mannitol challenge
Description: Mannitol inhalation challenge will be administered to both male and females with asthma

Intervention type: DIAGNOSTIC_TEST
Intervention: Mannitol challenge
Description: Mannitol inhalation challenge will be administered to both male and females with asthma
Study: NCT05010980

Intervention type: OTHER
Intervention: CMR
Description: clinical indication

Intervention type: OTHER
Intervention: CMR
Description: clinical indication

Intervention type: OTHER
Intervention: scintigraphy
Description: clinical indication

Intervention type: OTHER
Intervention: scintigraphy
Description: clinical indication
Study: NCT05007756

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB Challenge
Description: UVB challenge will be administered dermally through Lumera Phototherapy System.
Study: NCT05282771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study: NCT05975645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab injection
Description: Penpulimab is an inhibitor of programmed cell death 1 (PD-1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT04976686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Participants will reduce their carbohydrate consumption to 80g daily
Study: NCT04520971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 780G
Description: 780G closed-loop insulin delivery system (Medtronic)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: continue with standard of care treatment (pump without closed-loop or MDI)
Study: NCT05938075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: Sterile suspension for injection
Study: NCT05566028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745 formulation I
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745 formulation II
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D745 Placebo
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Study: NCT04566120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinnamon extract mouthwash
Description: cinnamon extract mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorohexidine based mouthwash
Description: chlorohexidine based mouthwash
Study: NCT06114186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data
Description: using remote monitoring and real-time glucose data sharing with a Follower.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: self reported HbA1C or GMI
Study: NCT05277558

Intervention type: OTHER
Intervention: Observational
Description: Investigators are observing brain health over time (21 months) in these groups

Intervention type: OTHER
Intervention: Observational
Description: Investigators are observing brain health over time (21 months) in these groups

Intervention type: OTHER
Intervention: Observational
Description: Investigators are observing brain health over time (21 months) in these groups
Study: NCT06465004

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of protein - rich drink
Description: The participants will drink on of three protein - rich drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of protein - rich drink
Description: The participants will drink on of three protein - rich drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of protein - rich drink
Description: The participants will drink on of three protein - rich drinks
Study: NCT05594225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Neuromuscular/Dual-Task Training
Description: The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
Study: NCT05612113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Supervision + Session Goal Formulation
Description: Read under Arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Session Goal Formulation
Description: Read under Arms
Study: NCT05587907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitLight Trainer
Description: Evaluation of the reaction time before and after special training program using visual stimuli.
Study: NCT05667740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma-PN3
Description: Inactivated whole-cell pneumococcal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar-13
Description: Licensed polysaccharide conjugate pneumococcal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23
Description: Licensed polysaccharide pneumococcal vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06375317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
Description: PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses.
Study: NCT04891497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 240mg orally twice daily for 3 consecutive days
Study: NCT06165042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass hybrid restorative system
Description: In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish + Glass hybrid restorative system
Description: In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
Study: NCT04728386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: curcumin solution
Description: 2 % curcumin solution as root canal irrigant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium hypochlorite
Description: 2.5% sodium hypochlorite solution as root canal irrigant
Study: NCT04891380

Intervention type: DEVICE
Group type: OTHER
Intervention: LUCAS 2 Active Decompression 2
Description: Chest compression with active decompression of the chest. Measurement of physiological parameters.

Intervention type: DEVICE
Group type: OTHER
Intervention: LUCAS 2 Active Decompression 2
Description: Chest compression with active decompression of the chest. Measurement of physiological parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Hypotension
Description: measurement of physiological parameters

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive care transport
Description: Measurement of physiological parameters
Study: NCT05357027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-E202 cells
Description: T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Capsules
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT04184609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: In this condition, the participants will not receive any medications or drugs before exercise
Study: NCT05720390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-leucine
Description: L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of quinine and L-leucine
Description: In this condition, both quinine and L-leucine will be administered as 'active'.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
Study: NCT05948631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISC intervention
Description: MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
Study: NCT04759157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-based treatment
Description: Couples will attend 3, video based sessions for couples-based treatment
Study: NCT04184609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 180 mcg of Albuterol will be administered before exercise
Study: NCT05851521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary prostatic stent (Exime®)
Description: Placement of temporary prostatic stent (Exime®) following the procedure described in the product information

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling catheter
Description: Placement of indwelling catheter
Study: NCT06255132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated pupillometer NPi-200
Description: Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon).
Study: NCT04759157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-based treatment
Description: Couples will attend 3, video based sessions for couples-based treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized education
Description: Patients will receive standardized educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized education
Description: Patients will receive standardized educational materials
Study: NCT04847427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core exercises training
Description: Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural exercises training
Description: Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric exercises training
Description: Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control trial
Description: Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
Study: NCT05480852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bis-GMA Free dental resin composite
Description: Restorative Material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bis-GMA Free dental resin composite
Description: Restorative Material